<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Centruroides (scorpion) antivenom: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Centruroides (scorpion) antivenom: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Centruroides (scorpion) antivenom: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="16767" href="/d/html/16767.html" rel="external">see "Centruroides (scorpion) antivenom: Drug information"</a> and <a class="drug drug_patient" data-topicid="16768" href="/d/html/16768.html" rel="external">see "Centruroides (scorpion) antivenom: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F13215077"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Anascorp</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F14181853"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antivenin</span></li></ul></div>
<div class="block don drugH1Div" id="F53462634"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9e288f4c-9e8a-4c01-9b48-9eeed22f9317">Scorpion envenomation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Scorpion envenomation: </b>IV: Initial: 3 vials (containing ≤105 mg total protein [as of 6/2021 manufacturer's labeling, previous amount ≤57 mg] and ≥450 LD50 [mouse] neutralizing units) initiated as soon as possible after scorpion sting in patients who develop clinically important signs of envenomation; may administer additional vials in 1-vial increments every 30 to 60 minutes as needed.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F13168393"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9e288f4c-9e8a-4c01-9b48-9eeed22f9317">Scorpion envenomation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Scorpion envenomation:</b> Infants, Children, and Adolescents: IV: Initial: 3 vials (containing ≤105 mg total protein [as of 6/2021 manufacturer's labeling, previous amount ≤57 mg] and ≥450 LD50 [mouse] neutralizing units) initiated as soon as possible after scorpion sting in patients who develop clinically important signs of envenomation; may administer additional vials in 1-vial increments every 30 to 60 minutes as needed; typical reported dosage range: 1 to 5 vials (Boyer 2013; Hurst 2018).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51084395"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51084396"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F13168394"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="16767" href="/d/html/16767.html" rel="external">see "Centruroides (scorpion) antivenom: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9e288f4c-9e8a-4c01-9b48-9eeed22f9317">Scorpion envenomation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Scorpion envenomation:</b>
<b>Note:</b> Initiate therapy as soon as possible after scorpion sting in patients who develop clinically important signs of scorpion envenomation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> Initial: 3 vials (containing ≤105 mg total protein [as of 6/2021 manufacturer's labeling, previous amount ≤57 mg] and ≥450 LD50 [mouse] neutralizing units); may administer additional vials in 1-vial increments every 30 to 60 minutes as needed. Typical dosage range: 1 to 5 vials (Boyer 2013; Hurst 2018).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50992068"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50989389"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F13168372"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults and pediatrics.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (2%), skin rash (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (1%), nausea (2%), vomiting (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (2%), headache (2%), lethargy (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myalgia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (1%), rhinorrhea (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (4%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Hypersensitivity: Serum sickness-like reaction</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Cardiovascular: Chest tightness, palpitations</p></div>
<div class="block coi drugH1Div" id="F13168369"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed within the manufacturer’s labeling.</p></div>
<div class="block war drugH1Div" id="F13168370"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concern related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acute hypersensitivity reactions: Derived from equine (horse) immune globulin F(ab’)<sub>2</sub> fragments; anaphylaxis and anaphylactoid reactions are possible, especially in patients with known allergies to horse protein. However, due to the lower protein content, purity, and absence of the immunogenic Fc portion of the immunoglobulin, serious adverse events are uncommon; in a prospective study (n=1,534), the incidence of acute antivenom reactions and type 3 immune reactions was 0.2% (n=3) and 0.5% (n=8), respectively (Boyer 2013). Patients who have had previous treatment with <i>Centruroides</i> immune F(ab’)<sub>2</sub> or other equine-derived antivenom/antitoxin may be at a higher risk for hypersensitivity reactions. In patients who develop an anaphylactic reaction, discontinue the infusion and administer emergency care. Immediate treatment (eg, epinephrine 1 mg/mL, corticosteroids, diphenhydramine) should be available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Delayed serum sickness: Delayed serum sickness may occur, usually within 2 weeks; monitor patients with follow-up visits for signs and symptoms (eg, arthralgia, fever, myalgia, rash).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form related issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cresol: Product may contain small amounts of cresol resulting from the manufacturing process; local reactions and myalgias may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Disease transmission: Product of equine (horse) plasma; may potentially contain infectious agents (eg, viruses) which could transmit disease.</p></div>
<div class="block foc drugH1Div" id="F13168512"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anascorp:  (1 ea) [contains cresol]</p></div>
<div class="block geq drugH1Div" id="F20452408"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block admp drugH1Div" id="F52614113"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Administer over 10 minutes; others have reported beginning infusion slower at 25 to 50 mL/hour and then double the rate every 5 minutes as tolerated (Tuuri 2011); monitor for return of symptoms of envenomation and repeat as needed. Medications (eg, epinephrine, corticosteroids, diphenhydramine) and equipment for resuscitation should be readily available in case of hypersensitivity reactions. IM administration should generally be avoided since the time to peak blood concentration may be prolonged with this route of administration (Tuuri 2011; Vasquez 2010). If unable to obtain intravenous access, intraosseous (full dose) and intramuscular (single vial dose) administration have been reported in a neonate and a 16 month old child (Hiller 2010).</p></div>
<div class="block adm drugH1Div" id="F13168397"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Administer over 10 minutes; monitor for return of symptoms of envenomation and repeat as needed. Medications (eg, epinephrine, corticosteroids, diphenhydramine) and equipment for resuscitation should be readily available in case of hypersensitivity reactions. Avoid IM since the time to peak blood concentration may be prolonged with this route of administration (Tuuri 2011; Vasquez 2010).</p></div>
<div class="block sts drugH1Div" id="F13168379"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Store unused vials at room temperature of 25°C (77°F); excursions permitted up to 40°C (104°F); do not freeze. Discard partially used vials.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Pharmacy supply of emergency antidotes:</i> Guidelines suggest that at least 3 vials of <i>Centruroides</i> immune F(ab’)<sub>2</sub> be stocked in endemic areas. Suggested amount is stated to be a sufficient quantity to treat 1 patient weighing 100 kg for an initial 8- to 24-hour period (Dart 2018); actual amount to be stocked should take into account site-specific and population-specific needs.</p></div>
<div class="block usep drugH1Div" id="F53569825"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of scorpion envenomation in patients with clinical signs of envenomation (FDA approved in ages of neonates through adults)</p></div>
<div class="block cyt drugH1Div" id="F13299002"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F13225889"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F13168367"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Animal reproduction studies have not been conducted.</p>
<p style="text-indent:0em;margin-top:2em;">Outcome data following use of <i>Centruroides</i> immune F(ab’)<sub>2</sub> during pregnancy are limited (Boyer 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Scorpion stings may be associated with adverse pregnancy outcomes, depending on the degree of envenomation (Dorce 2017; Shah 2016). In general, medications used as antidotes should take into consideration the health and prognosis of the patient; antidotes should be administered to pregnant patients if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003). Pregnant patients experiencing severe pain refractory to reasonable doses of opioids or systemic effects (eg, loss of muscle control, respiratory distress) should be considered for antivenom therapy (Brown 2013; Shah 2016).</p></div>
<div class="block mopp drugH1Div" id="F53569745"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs and symptoms of envenomation (eg, opsoclonus, involuntary muscle movement, slurred speech, paresthesias, respiratory distress, salivation, frothy sputum, vomiting); signs and symptoms of acute antivenom hypersensitivity reactions (eg, urticaria, dyspnea); follow-up visits for signs and symptoms of serum sickness (eg, arthralgia, fever, myalgia, rash)</p></div>
<div class="block pha drugH1Div" id="F13168385"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Contains venom-specific F(ab’)<sub>2</sub> fragments of IgG which bind and neutralize venom toxins; thereby helping to remove the toxin from the target tissue and eliminate it from the body.</p></div>
<div class="block phk drugH1Div" id="F13168387"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset: Time to resolution of symptoms: Adults: 1.91 ± 1.4 hours; Children: 1.28 ± 0.8 hours; &gt;95% of all patients will experience resolution of symptoms within 4 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 13.6 L ± 5.4 L</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life, elimination: 159 ± 57 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58201934"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Soro antiescorpionico</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Anascorp (centruroides immune F[ab’]2 [equine]) [prescribing information]. Franklin, TN: Rare Disease Therapeutics; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Anascorp.2">
<a name="Anascorp.2"></a>Anascorp (centruroides [scorpion] immune F[ab’]2 [equine]) [prescribing information]. Franklin, TN: Rare Disease Therapeutics Inc; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12769509">
<a name="12769509"></a>Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/centruroides-scorpion-antivenom-pediatric-drug-information/abstract-text/12769509/pubmed" id="12769509" target="_blank">12769509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23916602">
<a name="23916602"></a>Boyer L, Degan J, Ruha AM, Mallie J, Mangin E, Alagón A. Safety of intravenous equine F(ab')2: insights following clinical trials involving 1534 recipients of scorpion antivenom. <i>Toxicon</i>. 2013;76:386-393.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/centruroides-scorpion-antivenom-pediatric-drug-information/abstract-text/23916602/pubmed" id="23916602" target="_blank">23916602</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19439743">
<a name="19439743"></a>Boyer LV, Theodorou AA, Berg RA, et al. Antivenom for critically ill children with neurotoxicity from scorpion stings. <i>N Engl J Med</i>. 2009;360(20):2090-2098. doi:10.1056/NEJMoa0808455<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/centruroides-scorpion-antivenom-pediatric-drug-information/abstract-text/19439743/pubmed" id="19439743" target="_blank">19439743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23298218">
<a name="23298218"></a>Brown SA, Seifert SA, Rayburn WF. Management of envenomations during pregnancy. <i>Clin Toxicol (Phila)</i>. 2013;51(1):3-15.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/centruroides-scorpion-antivenom-pediatric-drug-information/abstract-text/23298218/pubmed" id="23298218" target="_blank">23298218</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27487782">
<a name="27487782"></a>Coorg V, Levitan RD, Gerkin RD, Muenzer J, Ruha AM. Clinical presentation and outcomes associated with different treatment modalities for pediatric bark scorpion envenomation. <i>J Med Toxicol</i>. 2017;13(1):66-70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/centruroides-scorpion-antivenom-pediatric-drug-information/abstract-text/27487782/pubmed" id="27487782" target="_blank">27487782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28669553">
<a name="28669553"></a>Dart RC, Goldfrank LR, Erstad BL, et al. Expert consensus guidelines for stocking of antidotes in hospitals that provide emergency care.<i> Ann Emerg Med</i>. 2018;71(3):314-325.e1. doi:10.1016/j.annemergmed.2017.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/centruroides-scorpion-antivenom-pediatric-drug-information/abstract-text/28669553/pubmed" id="28669553" target="_blank">28669553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28630618">
<a name="28630618"></a>Dorce ALC, Martins ADN, Dorce VAC, Nencioni ALA. Perinatal effects of scorpion venoms: maternal and offspring development<i>. J Venom Anim Toxins Incl Trop Dis</i>. 2017;23:31. doi:10.1186/s40409-017-0121-z<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/centruroides-scorpion-antivenom-pediatric-drug-information/abstract-text/28630618/pubmed" id="28630618" target="_blank">28630618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20728778">
<a name="20728778"></a>Hiller K, Jarrod MM, Franke HA, et al, "Scorpion Antivenom Administered by Alternative Infusions," <i>Ann Emerg Med</i>, 2010, 56(3):309-10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/centruroides-scorpion-antivenom-pediatric-drug-information/abstract-text/20728778/pubmed" id="20728778" target="_blank">20728778</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28871821">
<a name="28871821"></a>Hurst NB, Lipe DN, Karpen SR, et al. Centruroides sculpturatus envenomation in three adult patients requiring treatment with antivenom. <i>Clin Toxicol (Phila).</i> 2018;56(4):294-296. doi:10.1080/15563650.2017.1371310<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/centruroides-scorpion-antivenom-pediatric-drug-information/abstract-text/28871821/pubmed" id="28871821" target="_blank">28871821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27255088">
<a name="27255088"></a>Shah N, Martens MG. Scorpion envenomation in pregnancy.<i> South Med J</i>. 2016;109(6):338-341. doi:10.14423/SMJ.0000000000000470<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/centruroides-scorpion-antivenom-pediatric-drug-information/abstract-text/27255088/pubmed" id="27255088" target="_blank">27255088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21730810">
<a name="21730810"></a>Tuuri RE, Reynolds S. Scorpion envenomation and antivenom therapy. <i>Pediatr Emerg Care</i>. 2011;27(7):667-675.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/centruroides-scorpion-antivenom-pediatric-drug-information/abstract-text/21730810/pubmed" id="21730810" target="_blank">21730810</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20849955">
<a name="20849955"></a>Vasquez H, Chavez-Haro A, Garcia-Ubbelohde W, et al. Pharmacokinetics of a F(ab’)2 scorpion antivenom administered intramuscularly in healthy human volunteers. <i>Int Immunopharmacol</i>. 2010;10(11):1318-1324.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/centruroides-scorpion-antivenom-pediatric-drug-information/abstract-text/20849955/pubmed" id="20849955" target="_blank">20849955</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 83876 Version 77.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
